Janssen Pharmaceuticals Inc.

10/15/2021 | Press release | Distributed by Public on 10/15/2021 08:13

OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.